| Date | Quarter | Session | EPS (est → actual) | Revenue (est → actual) |
|---|---|---|---|---|
| Oct 28, 2026Next | Q3 2026 | — | 2.19 | 7.94 B |
Sep 1, 2026
GILD's FDA approval of Bixlenvo expands its HIV portfolio with a first-of-its-kind single-tablet option for underserved patients.
Gilead (GILD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Based on the average brokerage recommendation (ABR), Gilead (GILD) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Aug 31, 2026
The FDA approved Gilead Sciences' Bixlenvo, a new once-daily single tablet regimen for virologically suppressed adults treating HIV.
Aug 28, 2026
GILD wins FDA approval for Bixlenvo, a once-daily HIV regimen offering a smaller single-tablet option for patients on complex therapies.
Aug 27, 2026
Gilead Sciences has delivered strong share price gains over the past five years, yet based on broad valuation checks it still screens as inexpensive relative to its fundamentals. For investors, the stock now sits in an interesting spot where a powerful HIV and oncology franchise is reflected in the price to some extent, but the broader valuation read still points to room for a more optimistic view than the market currently implies. Over the past 5 years, Gilead Sciences has returned about...
FOSTER CITY, Calif., August 27, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) approved Bixlenvo™ (bictegravir 75 mg/lenacapavir 50 mg), the smallest once-daily single tablet regimen (STR) for the treatment of HIV in adults who are virologically suppressed. Bixlenvo is now the first and only STR option for virologically suppressed people with HIV who are on complex regimens and unable to take currently available STRs.
CNBC's Annika Kim Constantino reports on the FDA's decision to approve Gilead's daily HIV pill.
Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the U.S. Food and Drug Administration (FDA) approved Bixlenvo™ (bictegravir 75 mg/lenacapavir 50 mg), the smallest once-daily single tablet regimen (STR) for the
The new pill is also aimed at people who are doing well on a single-tablet regimen, including Biktarvy, and want to switch to a new treatment.
Gilead Sciences (GILD) is back in focus after the European Commission approved Trodelvy plus Keytruda for certain first line metastatic triple negative breast cancer patients, expanding the company’s oncology franchise in Europe. For investors tracking the bigger picture, Gilead Sciences’ 1 month share price return of 10.25% and year to date share price return of 21.78% point to firming momentum. The 1 year total shareholder return of 34.99% and 5 year total shareholder return of 145.70%...
Gilead Sciences (NasdaqGS:GILD) received expanded European Commission approval for Trodelvy in combination with Keytruda as a first-line treatment for metastatic triple-negative breast cancer across PD-L1 status in Europe. The decision establishes Trodelvy plus Keytruda as the first antibody-drug conjugate and immunotherapy combination approved for first-line metastatic TNBC across the European Union. The ruling broadens Trodelvy’s addressable patient population in Europe and further...
Aug 26, 2026
FOSTER CITY, Calif., August 26, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences:
Since earnings, investors have focused mainly on the biotech company's growth potential with its HIV PrEP medicines.
Aug 24, 2026
The European Commission on Monday authorized Trodelvy combined with Merck’s (MRK) Keytruda for certain adults with previously untreated advanced or metastatic triple-negative breast cancer.
